Form 4 for BBIO BridgeBio Pharma, Inc.
Accepted 2025-06-26 00:00:00 ET · period of report 2025-06-24 · accession 0000950170-25-090498 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TI | 2025-06-26 | 2025-06-24 | BBIO | MCCORMICK FRANK | Dir | S - Sale | $44.23 | -100.0K | 880.0K | -10% | -$4.42M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-06-24 | S | D | 100,000 | $44.23 | 879,979 | I By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017 | — | — | (F2) Represents the weighted average sale price of the shares sold from $44.00 to $44.69 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |